- Home
- MHF vs CRGX Comparison
MHF vs CRGX Comparison
Compare MHF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHF
- CRGX
- Stock Information
- Founded
- MHF 1988
- CRGX 2021
- Country
- MHF United States
- CRGX United States
- Employees
- MHF N/A
- CRGX N/A
- Industry
- MHF Finance/Investors Services
- CRGX
- Sector
- MHF Finance
- CRGX
- Exchange
- MHF Nasdaq
- CRGX Nasdaq
- Market Cap
- MHF 149.7M
- CRGX 190.0M
- IPO Year
- MHF N/A
- CRGX 2023
- Fundamental
- Price
- MHF $7.02
- CRGX $4.20
- Analyst Decision
- MHF
- CRGX Hold
- Analyst Count
- MHF 0
- CRGX 7
- Target Price
- MHF N/A
- CRGX $4.67
- AVG Volume (30 Days)
- MHF 57.2K
- CRGX 591.0K
- Earning Date
- MHF 01-01-0001
- CRGX 08-11-2025
- Dividend Yield
- MHF 4.29%
- CRGX N/A
- EPS Growth
- MHF N/A
- CRGX N/A
- EPS
- MHF N/A
- CRGX N/A
- Revenue
- MHF N/A
- CRGX N/A
- Revenue This Year
- MHF N/A
- CRGX $57.81
- Revenue Next Year
- MHF N/A
- CRGX N/A
- P/E Ratio
- MHF N/A
- CRGX N/A
- Revenue Growth
- MHF N/A
- CRGX N/A
- 52 Week Low
- MHF $5.92
- CRGX $3.00
- 52 Week High
- MHF $6.79
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- MHF 50.34
- CRGX 44.13
- Support Level
- MHF $6.89
- CRGX $4.07
- Resistance Level
- MHF $6.90
- CRGX $4.31
- Average True Range (ATR)
- MHF 0.06
- CRGX 0.17
- MACD
- MHF 0.02
- CRGX -0.03
- Stochastic Oscillator
- MHF 75.00
- CRGX 18.62
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.